QIAGEN leverages QuantiFERON®-TB technology to advance global efforts against TB TB IGRA testing now accessible in high burden, low resource and decentralized settings Study data also showcased at the ...

QuantiFERON franchise benefits from new applications, products and automation options, building on strengths in tuberculosis detection while addressing new disease targets QuantiFERON SARS-CoV-2 assay ...

HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...

QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...

QIAGEN QGEN recently made progress in tuberculosis (TB) testing. The company announced that a new, systematic review of the clinical relevance of test values from the company’s proprietary ...

Tuberculosis (TB) remains a persistent challenge to global public health, claiming nearly 1.5 million lives each year. Screening populations at risk for latent TB infection has emerged as a vital ...

To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...

HILDEN, Germany & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch and CE marking of QIAreach® QuantiFERON®-TB test for tuberculosis ...

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has gained additional momentum with the approval of the fourth ...